Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Echo Therapeutics logo — company profile

Echo Therapeutics

Founded 1989 United States United States 8 employees Post-IPO Debt Total: $44.70M Biotechnology, Health Care +2

General Information

Company Name Echo Therapeutics
Founded Year 1989
Location United States United States
Founders / Decision Makers
Team member
Employees 8
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Echo Therapeutics. To contact Echo Therapeutics, visit echotx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Echo Therapeutics compare?

A PDF of Echo Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Echo Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Echo Therapeutics

Echo Therapeutics, established in 1989, focuses on developing a non-invasive, wireless, continuous glucose monitoring (CGM) system. The company's CGM system holds potential for application in the outpatient diabetes market, as well as in the fitness, weight loss, and wearable-health sector. Additionally, it presents a longer-term opportunity in hospital settings. Echo has also introduced a needle-free skin preparation device as a platform technology, enabling improved skin permeation for the extraction of analytes, including glucose, and enhanced delivery of topical pharmaceuticals. The company, headquartered in the United States, received a $1.79M Post-IPO Debt investment on February 8, 2016. Although the last investment details do not specify the investors, this funding underscores investor interest in Echo Therapeutics' innovative approach in the Biotechnology, Health Care, Health and Wellness, and Medical Devices industries.

Business keywords: medical device, glucose monitoring, continuous glucose monitoring, wearable health technology, diabetes management, non-invasive sensing, skin preparation technology, transdermal drug delivery, hospital critical care, wireless health monitoring

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $1.79M -
08 Feb 2016
Post IPO Equity $4.00M -
22 Dec 2014
Post IPO Equity $10.00M 2
Platinum Management (NY) LLC
Platinum Management (NY) LLC, Medical Technologies Innovation Asia
19 Dec 2013
Post IPO Equity $12.50M -
20 Jun 2013
Post IPO Equity $2.90M -
15 Feb 2011
Post IPO Equity $5.50M 1
Platinum-Montaur Life Sciences
06 Jan 2011
Post IPO Equity $2.46M -
21 Oct 2010
Post IPO Equity $562.50K -
03 Dec 2009
Post IPO Equity $3.00M -
13 Nov 2009
Post IPO Equity $2.00M -
29 Jul 2009

Echo Therapeutics Alternatives & Competitors

View All Alternatives
Echo Therapeutics vs
Transdermal Diagnostics Ltd
Transdermal Diagnostics Ltd

The world's first wearable for non-invasive continuous biomarker co-monitoring.

Seed
10 employees
Biotechnology, Health Care
Echo Therapeutics vs
Apollon
Apollon Korea South

The wearable that reads your glucose

Seed
40 employees
Biotechnology, Health Care
Compare Echo Therapeutics vs Apollon
Echo Therapeutics vs
GlucoActive Sp. z o.o.
GlucoActive Sp. z o.o. Poland

A wearable device for non-invasive measurement of blood glucose concentration using spectrophotometr...

Seed
19 employees
Biotechnology, Hardware
Also compare with: Echo Therapeutics vs Senseonics, Incorporated Senseonics, Incorporated View all alternatives

FAQ About Echo Therapeutics

Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company’s CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term oppo...
Echo Therapeutics was founded in 1989.
Echo Therapeutics is headquartered in United States.
Echo Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Medical Devices. Its work centres on medical device, glucose monitoring, continuous glucose monitoring and wearable health technology.
Echo Therapeutics has approximately 8 employees.
Echo Therapeutics has completed 10 funding rounds, raising a total of $44.70M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Echo Therapeutics include Transdermal Diagnostics Ltd, Apollon, GlucoActive Sp. z o.o., NIQS Tech, GraphWear Technologies Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Echo Therapeutics and Transdermal Diagnostics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Echo Therapeutics, https://bouncewatch.com/company/echo-therapeutics, updated 3 March 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes